KYORIN Pharmaceutical Co.,Ltd. (4569) AI Stock Analysis

• Market Cap: ¥79.70B
• Dividend Yield: 3.43%
• Average Volume (3M): 67.41K
• Price to Earnings (P/E): 8.5
• Beta (1Y): 0.52
• Revenue Growth: 9.83%
• EPS Growth: 86.18%
• Country: JP
• Employees: 2,042
• Sector: Healthcare
• Sector Strength: 46
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 36.57
• Shares Outstanding: 59,945,640
• 10 Day Avg. Volume: 63,890
• 30 Day Avg. Volume: 67,406
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥1,706.00
• Price Target Upside: 12.68% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 77 Outperform
• Price Target: ¥1,706.00 ▲(12.68% Upside)

KYORIN Pharmaceutical's strong valuation and positive technical indicators are the main contributors to the score. The company's financial performance is solid, with growth and profitability improvements, but liquidity concerns due to negative free cash flow remain a risk. The absence of earnings call data and corporate events does not affect the overall score.

KYORIN Pharmaceutical Co.,Ltd. Business Overview & Revenue Model

Company Description

KYORIN Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company engaged in the research, development, manufacturing, and marketing of pharmaceutical products. The company primarily focuses on respiratory, otolaryngology, urology, and infectious diseases. Its core products include prescription medicines, over-the-counter drugs, and consumer healthcare products. KYORIN Pharmaceutical is committed to improving health and quality of life through innovative solutions and medical advancements.

How the Company Makes Money

KYORIN Pharmaceutical Co., Ltd. generates revenue primarily through the sale of its pharmaceutical products. The company's key revenue streams include the domestic and international sales of prescription drugs, particularly in its specialized fields such as respiratory and infectious diseases. Additionally, KYORIN invests in research and development to create new drugs and improve existing formulations, which can lead to additional revenue streams through licensing and partnerships. The company also benefits from strategic collaborations with other pharmaceutical firms for distribution and co-development, enhancing its market reach and revenue potential. KYORIN's earnings are influenced by factors such as regulatory approvals, patent protection, and market demand for its products.

KYORIN Pharmaceutical Co.,Ltd. Financial Statement Overview

Summary

KYORIN Pharmaceutical shows robust revenue growth and improved profitability margins, supported by effective cost management and operational efficiency. The balance sheet is stable with a low debt-to-equity ratio, indicating financial stability. However, declining cash reserves and negative free cash flow suggest liquidity challenges and highlight areas needing improvement in cash management.

Income Statement

KYORIN Pharmaceutical has demonstrated robust revenue growth with a significant increase of 8.83% from 2024 to 2025. The gross profit margin remains strong at 45.75%, indicating effective cost management. Notably, the net profit margin improved to 6.98%, reflecting enhanced profitability. EBIT and EBITDA margins also saw positive trends, showcasing improved operational efficiency. However, the fluctuations in EBIT and EBITDA margins over the years suggest potential volatility in operational performance.

Balance Sheet

The company's balance sheet reflects solid equity with an equity ratio of 70.39%, suggesting financial stability. The debt-to-equity ratio is relatively low at 0.21, indicating conservative leverage. Return on equity stands at 6.67%, showing moderate profitability on shareholders' investments. However, the decrease in cash and equivalents over the years could be a concern for liquidity management.

Cash Flow

The cash flow statement reveals a challenging scenario with negative free cash flow growth, moving from -4.70 billion JPY in 2024 to -2.19 billion JPY in 2025. The operating cash flow to net income ratio is low at 0.39, suggesting inefficiencies in converting profits to cash flows. However, the free cash flow to net income ratio reflects some improvement, albeit still negative, indicating potential cash management issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	130.09B	130.09B	119.53B	113.27B	105.53B	102.90B
Gross Profit	59.53B	59.51B	51.41B	50.17B	49.44B	51.63B
EBITDA	17.55B	17.55B	11.37B	10.81B	8.72B	11.98B
Net Income	9.09B	9.09B	5.32B	4.72B	3.93B	6.13B
Balance Sheet
Total Assets	193.62B	193.62B	177.68B	176.04B	171.92B	167.13B
Cash, Cash Equivalents and Short-Term Investments	16.51B	16.51B	13.98B	19.39B	27.49B	30.84B
Total Debt	28.44B	28.44B	20.95B	21.28B	21.62B	21.88B
Total Liabilities	57.33B	57.33B	46.90B	50.59B	47.42B	42.47B
Stockholders Equity	136.28B	136.28B	130.78B	125.46B	124.51B	124.66B
Cash Flow
Free Cash Flow	0.00	-2.19B	-4.70B	-7.40B	3.66B	65.00M
Operating Cash Flow	0.00	3.51B	1.55B	2.01B	6.35B	5.19B
Investing Cash Flow	0.00	-6.32B	-3.19B	-6.28B	-2.56B	-4.26B
Financing Cash Flow	0.00	3.95B	-3.35B	-3.36B	-4.11B	-4.92B

KYORIN Pharmaceutical Co.,Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1514.00
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4569, the sentiment is Neutral. The current price of 1514 is below the 20-day moving average (MA) of 1553.45, below the 50-day MA of 1520.26, and above the 200-day MA of 1468.17, indicating a neutral trend. The MACD of 3.09 indicates Positive momentum. The RSI at 39.10 is Neutral, neither overbought nor oversold. The STOCH value of 5.27 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4569.

KYORIN Pharmaceutical Co.,Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4569	77 Outperform	¥79.70B	8.48		3.43%	9.83%	86.18%
Sector *	51 Neutral	$7.85B	-0.18	-40.01%	2.28%	22.97%	-2.05%
KSPHF	―	$1.19B	15.02	5.93%	2.33%	―	―
TRXPF	―	$1.21B	28.51	4.52%	―	―	―
TWAPF	―	$970.51M	11.76	9.60%	1.44%	―	―
MFY	―	€620.49M	17.19	4.88%	―	―	―
4886	74 Outperform	¥65.20B	13.64		2.05%	6.23%	-31.45%

KYORIN Pharmaceutical Co.,Ltd. Corporate Events

KYORIN Pharmaceutical Reports Strong Quarterly Growth Amidst Challenging Full-Year Outlook

KYORIN Pharmaceutical Co., Ltd. reported significant growth in its financial performance for the three months ended June 30, 2025, with net sales increasing by 6.4% and operating profit surging by 106% compared to the same period last year. Despite the positive quarterly results, the company forecasts a decline in full-year profits, indicating potential challenges ahead.

KYORIN Pharmaceutical Announces Dividend Distribution

KYORIN Pharmaceutical Co., Ltd. announced a resolution to distribute dividends from retained earnings, with a record date of March 31, 2025. Shareholders will receive a year-end dividend of ¥37.00 per share, which includes an ordinary dividend of ¥32.00 and a special dividend of ¥5.00, resulting in an annual dividend of ¥57.00 per share. This decision reflects the company’s strong financial performance and commitment to returning value to its shareholders.

KYORIN Pharmaceutical Announces Executive Personnel Changes

KYORIN Pharmaceutical Co., Ltd. announced executive personnel changes effective June 20, 2025, involving key positions within its Board of Directors and Corporate Officers. These changes are part of the company’s strategic realignment to enhance operational efficiency and strengthen leadership within its group facilities.

KYORIN Pharmaceutical to Cancel 7.2% of Treasury Shares to Boost Capital Efficiency

KYORIN Pharmaceutical Co., Ltd. has announced the cancellation of 4,662,295 treasury shares, representing 7.2% of its total issued shares, to enhance capital efficiency and shareholder returns. This strategic move is expected to positively impact the company’s financial structure and shareholder value, with the cancellation scheduled for May 30, 2025.

KYORIN Pharmaceutical Announces Special Dividend Amid Profit Surge

KYORIN Pharmaceutical Co., Ltd. announced a special dividend of 5.00 JPY per share for the fiscal year ending March 31, 2025, due to a significant increase in profit. This decision reflects the company’s strategy to balance growth investments and shareholder returns, resulting in a total annual dividend of 57.00 JPY per share.

KYORIN Pharmaceutical Reports Strong Financial Growth Amidst Upcoming Challenges

KYORIN Pharmaceutical Co., Ltd. reported significant financial growth for the fiscal year ending March 31, 2025, with an 8.8% increase in net sales and a 101.6% rise in operating profit compared to the previous year. The company also announced a special dividend, reflecting its strong financial performance. However, the forecast for the upcoming fiscal year indicates a decline in net sales and profits, suggesting potential challenges ahead. Changes in accounting policies have been implemented, affecting the reported figures for the previous fiscal year.